search
Back to results

Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)

Primary Purpose

Polyneuropathy, Polymyopathy

Status
Completed
Phase
Phase 1
Locations
Switzerland
Study Type
Interventional
Intervention
Neurally adjusted ventilatory assist (NAVA)
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Polyneuropathy focused on measuring critical associated illness polyneuropathy or polymyopathy (CIP/M)

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject itself or its next of kin has given written informed consent
  2. Independent physician has given written informed consent
  3. Male or female patients aged 18 - 80 years (extremes included).
  4. Mechanical ventilation for ≥ 48 hours prior to enrolment
  5. Presence of Critical Illness Polyneuropathy / Polymyopathy (CIP/M) according to the MRC Scale for Muscle Examination in 12 Muscle groups (Table 1) with or without loss of sensibility and muscle reflexes.
  6. Presence of at least one of the following risk factors (A - D) known to be associated with CIP/M. Note, the risk factor does not need to be present at enrolment but needs to have been present prior to enrolment during the actual stay in the ICU:

    • A: severe sepsis defined as the presence of an infection is highly suspected or proven and three or more of the following systemic inflammatory response syndrome (SIRS) criteria are met (Bernard et al 2001 s. Figure 15):

      • core temperature greater than 38 degrees celsius (100.4 degrees F) or less than 36 degrees celsius (96.8 degrees F);
      • heart rate greater than 90 beats per minute;
      • respiratory rate greater than 20 breaths per minute, or arterial carbon dioxide tension (Paco2) greater than 32 mm Hg, or mechanical ventilation for an acute process;
      • a white cell count of more than 12 000/mm3 or less than 4000/mm3 , or a differential count showing more than 10% immature neutrophils.
    • B: MODS (s. Figure 15)
    • C: treatment with corticosteroids for at least 24 hours (either as repeated bolus or as continuous infusion).
    • D: treatment with neuro-muscular blocking agents for at least 24 hours (either as repeated bolus or as continuous infusion).

Exclusion Criteria:

  1. Patient is less than 18 years or more than 80 years of age
  2. The attending physician refuses to allow enrollment
  3. The patient refuses informed consent
  4. Next of kin is unavailable or refuses informed consent
  5. The independent physician refuses informed consent
  6. Pregnant or breast-feeding female. A pregnancy test will be performed in all female patients less than 60 years of age
  7. Any contraindication to insertion/exchange a nasogastric tube, including (but not limited to): severe oropharyngeal malformation or bleeding; esophageal varices, tumor, infection, stenosis, or rupture, bleeding disorder with evidence of active bleeding.
  8. Presence or suspicion of diaphragm injury
  9. Presence or suspicion of a central nervous system (CNS) proximal of the spinal cord level C2) including (but not limited to): infarction, bleeding, tumor, or infection in the CNS
  10. Presence or suspicion of any preexisting peripheral neuromuscular disorder.
  11. History of heart and/or lung transplantation
  12. Any mechanical cardiac assist device (excluding intraaortic balloon pump)
  13. Any contraindication to reduce sedation or to stop neuromuscular blockage in order to allow spontaneous breathing
  14. The patient needs to be ventilated with a mode of mechanical ventilation that targets a redefined tidal volume or airway pressure as per attending physician
  15. Severe hemodynamic instability as per attending physician
  16. A fraction of inspired oxygen (FiO2) of > 0.8 at enrollment.
  17. The patient currently participates in another interventional clinical trial

Sites / Locations

  • Department of Intensive Care Medicine, University Hospital - Inselspital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NAVA

Arm Description

Outcomes

Primary Outcome Measures

Changes in mean inspiratory electrical activity of the diaphragm (Edi)

Secondary Outcome Measures

Changes in ventilatory and respiratory parameters Changes in sedative and vasoactive drugs used

Full Information

First Posted
January 31, 2008
Last Updated
February 2, 2011
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT00614562
Brief Title
Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)
Official Title
Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Neurally adjusted ventilatory assist (NAVA) is a new concept of mechanical ventilation. NAVA delivers assist to spontaneous breathing based on the detection of the electrical activity of the diaphragm. We study the effect of NAVA in patients with critical illness associated polyneuropathy / polymyopathy (CIP/M)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polyneuropathy, Polymyopathy
Keywords
critical associated illness polyneuropathy or polymyopathy (CIP/M)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NAVA
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Neurally adjusted ventilatory assist (NAVA)
Intervention Description
NAVA for 72 hours
Primary Outcome Measure Information:
Title
Changes in mean inspiratory electrical activity of the diaphragm (Edi)
Time Frame
beginning to end of study
Secondary Outcome Measure Information:
Title
Changes in ventilatory and respiratory parameters Changes in sedative and vasoactive drugs used
Time Frame
beginning to end of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject itself or its next of kin has given written informed consent Independent physician has given written informed consent Male or female patients aged 18 - 80 years (extremes included). Mechanical ventilation for ≥ 48 hours prior to enrolment Presence of Critical Illness Polyneuropathy / Polymyopathy (CIP/M) according to the MRC Scale for Muscle Examination in 12 Muscle groups (Table 1) with or without loss of sensibility and muscle reflexes. Presence of at least one of the following risk factors (A - D) known to be associated with CIP/M. Note, the risk factor does not need to be present at enrolment but needs to have been present prior to enrolment during the actual stay in the ICU: A: severe sepsis defined as the presence of an infection is highly suspected or proven and three or more of the following systemic inflammatory response syndrome (SIRS) criteria are met (Bernard et al 2001 s. Figure 15): core temperature greater than 38 degrees celsius (100.4 degrees F) or less than 36 degrees celsius (96.8 degrees F); heart rate greater than 90 beats per minute; respiratory rate greater than 20 breaths per minute, or arterial carbon dioxide tension (Paco2) greater than 32 mm Hg, or mechanical ventilation for an acute process; a white cell count of more than 12 000/mm3 or less than 4000/mm3 , or a differential count showing more than 10% immature neutrophils. B: MODS (s. Figure 15) C: treatment with corticosteroids for at least 24 hours (either as repeated bolus or as continuous infusion). D: treatment with neuro-muscular blocking agents for at least 24 hours (either as repeated bolus or as continuous infusion). Exclusion Criteria: Patient is less than 18 years or more than 80 years of age The attending physician refuses to allow enrollment The patient refuses informed consent Next of kin is unavailable or refuses informed consent The independent physician refuses informed consent Pregnant or breast-feeding female. A pregnancy test will be performed in all female patients less than 60 years of age Any contraindication to insertion/exchange a nasogastric tube, including (but not limited to): severe oropharyngeal malformation or bleeding; esophageal varices, tumor, infection, stenosis, or rupture, bleeding disorder with evidence of active bleeding. Presence or suspicion of diaphragm injury Presence or suspicion of a central nervous system (CNS) proximal of the spinal cord level C2) including (but not limited to): infarction, bleeding, tumor, or infection in the CNS Presence or suspicion of any preexisting peripheral neuromuscular disorder. History of heart and/or lung transplantation Any mechanical cardiac assist device (excluding intraaortic balloon pump) Any contraindication to reduce sedation or to stop neuromuscular blockage in order to allow spontaneous breathing The patient needs to be ventilated with a mode of mechanical ventilation that targets a redefined tidal volume or airway pressure as per attending physician Severe hemodynamic instability as per attending physician A fraction of inspired oxygen (FiO2) of > 0.8 at enrollment. The patient currently participates in another interventional clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lukas Brander, MD
Organizational Affiliation
Department of Intensive Care Medicine, University Hospital, Bern, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Intensive Care Medicine, University Hospital - Inselspital
City
Bern
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
10581089
Citation
Sinderby C, Navalesi P, Beck J, Skrobik Y, Comtois N, Friberg S, Gottfried SB, Lindstrom L. Neural control of mechanical ventilation in respiratory failure. Nat Med. 1999 Dec;5(12):1433-6. doi: 10.1038/71012. No abstract available.
Results Reference
background
PubMed Identifier
22048718
Citation
Tuchscherer D, Z'graggen WJ, Passath C, Takala J, Sinderby C, Brander L. Neurally adjusted ventilatory assist in patients with critical illness-associated polyneuromyopathy. Intensive Care Med. 2011 Dec;37(12):1951-61. doi: 10.1007/s00134-011-2376-0. Epub 2011 Nov 3.
Results Reference
derived

Learn more about this trial

Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)

We'll reach out to this number within 24 hrs